Biomerica Inc. (BMRA)
NASDAQ: BMRAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BMRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.97M
- Forward P/E
- 2.77
- EPS (TTM)
- -$1.64
- Dividend yield
- None
- 52-week range
- 1.01 – 2.94
- Day range
- 1.06 – 1.13
- Volume / Avg
- 5.38K / 72.95K
- Beta
- —
- Shares outstanding
- 4.60M
52-week range
BMRA stock today
Biomerica (BMRA) closed at $1.08 on Nov 20, down 0.92% (-$0.01), versus the S&P 500's 3.70% decline. Trading was light, with 5.38K shares changing hands, about 7% of the average daily volume. At this level, BMRA sits near the bottom of its 52-week range of $1.01 to $2.94: 63.3% below the high, set on Jan 7, 2026 and 6.9% above the low.
BMRA is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.6%. Biomerica has posted a net loss over the last twelve months (EPS of -$1.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Biomerica
Company profileBiomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Zackary S. Irani
- Headquarters
- Irvine, CA
- Employees
- 50
- Website
- biomerica.com
Financial highlights
Full financialsIn fiscal 2026, Biomerica generated $4.5 million in revenue, down 16.2% from fiscal 2025, its first annual decline since 2025. Biomerica reported a net loss of $3.8 million, compared with a loss of $5.0 million a year earlier. Gross margin was 8.1% (down from 9.4%) and operating margin -119.5%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $4.45M | $5.31M | $5.42M | $5.34M | $18.87M |
| Growth | -16.16% | -1.92% | +1.42% | -71.71% | +162.13% |
| Net income | $-3.77M | $-4.97M | $-5.98M | $-7.14M | $-4.53M |
| EPS (diluted) | $-1.30 | $-2.16 | $-2.84 | $-0.50 | $-0.36 |
Earnings
Earnings history- Last reported (Aug/2026)
- Oct 15, 2026
- EPS actual vs est.
- $-0.37 vs —
BMRA news
All BMRA newsBiomerica peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs BMRA |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs BMRA |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs BMRA |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs BMRA |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs BMRA |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs BMRA |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs BMRA |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs BMRA |
Indexes, lists and sector
Biomerica stock FAQ
What is Biomerica's stock price today?
BMRA last traded at $1.08 as of Nov 20, 4:00 PM EST, down 0.92% on the day. Prices are delayed at least 15 minutes.
Does Biomerica pay a dividend?
No. Biomerica does not currently pay a regular cash dividend.
Who is Biomerica's CEO?
Mr. Zackary S. Irani is the chief executive officer of Biomerica Inc., which has about 50 employees.
Has BMRA ever split its stock?
Yes. The most recent BMRA stock split was a 1-for-8 split on Apr 21, 2025, one of 2 splits on record.
What is the BMRA 52-week high?
The 52-week high for BMRA is $2.94 and the 52-week low is $1.01. The stock is currently 63.3% below its high.